ADCETRIS DIN 02401347
Health Canada record
| Active ingredient(s) | BRENTUXIMAB VEDOTIN 50 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FX05 BRENTUXIMAB VEDOTIN |
| Original market date | 19-Feb-2013 |
| Current status date | 09-Oct-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26050 | 2021-06-11 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 14056 | 2013-02-01 | New Drug Submission (NDS) |